1

### Iron metabolism disorders of patients with chronic 1 paracoccidioidomycosis 2

- 3
- 4

5	Eliana da Costa Alvarenga de Brito <sup>1</sup> ; Igor Valadares Siqueira <sup>2</sup> ; James Venturini <sup>1</sup> ; Vinícius
6	Lopes Teodoro Félix <sup>2</sup> ; Alana Oswaldina Gavioli Meira dos Santos <sup>3</sup> ; Rinaldo Poncio
7	Mendes <sup>1,4</sup> ; Simone Schneider Weber <sup>1,5</sup> ; Anamaria Mello Miranda Paniago <sup>1,3*</sup>
8	
9	
10	<sup>1</sup> Graduate Program in Infectious and Parasitic Diseases. Faculty of Medicine. Federal
11	University of Mato Grosso do Sul. Campo Grande, Mato Grosso do Sul, Brazil.
12	<sup>2</sup> Scientific initiation CNPq, Faculty of Medicine. Federal University of Mato Grosso do Sul,
13	Campo Grande, Mato Grosso do Sul, Brazil.
14	<sup>3</sup> Graduate Program in Health and Development of the Central West Region. Federal
15	University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
16	<sup>4</sup> Department of Tropical Diseases, Botucatu Medical School, Universidade Estadual Paulista
17	(UNESP), Botucatu, São Paulo, Brazil

18 <sup>5</sup> Faculty of Pharmaceutical Sciences, Food and Nutrition. Federal University of Mato Grosso

19 do Sul. Campo Grande, Mato Grosso do Sul, Brazil.

20

- 21 \* Corresponding author
- 22 E-mail: anamaria.paniago@ufms.br (AMMP)

# 24 Abstract

25 Paracoccidioidomycosis (PCM) is caused by *Paracoccidioides* spp.; during infection, some 26 host mechanisms limit the availability of iron, thereby reducing its reproduction. However, 27 Paracoccidioides spp. can evade the immune defense and, even under limited iron 28 conditions, use this mineral for growth and dissemination. This study evaluated the iron 29 metabolism of 39 patients who were diagnosed with chronic PCM between 2013 and 2021. 30 The forms of iron before treatment and at the time of clinical cure were evaluated based on 31 the following: serum ferritin levels (storage iron); total iron-binding capacity (TIBC) and 32 transferrin saturation (TSAT) level (transport iron); red blood cell (RBC), hemoglobin (Hb), 33 hematocrit (HCT), and soluble transferrin receptor (sTfR) levels; and sTfR/log ferritin ratio 34 (functional iron). The mean age of the patients was 54.5 years ( $\pm 6.7$  years). Most patients 35 were men (97.4%), rural workers (92.1%), and smokers (84.6%); most had moderate disease 36 severity (66.7%). Before treatment, the median values of all evaluated parameters were 37 within or just slightly outside the normal range of values. However, it is possible to infer that 38 PCM interferes with functional and storage iron because improvements in these parameters 39 after treatment as well as associations with disease severity were observed. Furthermore, 40 moderate correlations were observed between C-reactive protein and the Hb (r=-0.500; 41 p=0.002), RBC (r=-0.461; p=0.005), HCT (r=-0.514; p=0.001), and iron levels (r=-0.491; 42 p=0.002). PCM interferes with iron metabolism by transforming functional iron to storage 43 iron, as revealed by anemia, low iron levels with normal TSAT levels, normal TIBC, normal 44 sTfR levels, normal sTfR/log ferritin ratios, and normal or slightly increased ferritin levels. 45 PCM can lead to anemia of inflammation, which can be differentiated from iron deficiency 46 anemia by a careful investigation of the iron form parameters.

48 Keywords: anemia of inflammation; iron; iron metabolism; paracoccidioidomycosis;

*Paracoccidioides* spp.

# 54 Introduction

55 Paracoccidioidomycosis (PCM), which is a systemic mycosis endemic to Latin 56 America, is caused by dimorphic fungi, *Paracoccidioides* spp. Infection occurs through the inhalation of infective conidia that are present in the soil; these conidia settle in the lungs and 57 58 can spread to the lymphatic and hematogenous pathways and other organs. Brazil is the main 59 endemic area for PCM, which is considered the eighth leading cause of mortality associated 60 with chronic infectious diseases in the country [1]. Chronic or adult PCM, which is observed 61 in those older than age 30 years, is the most frequent form of this disease, and it 62 predominantly affects the lungs and mucous membranes of the upper digestive tract and 63 airways [2].

64 Similar to other fungal diseases, certain factors are determinants of PCM, such as the
65 inoculum size, pathogenicity, fungus virulence, defense system integrity, and genetic factors
66 [3]. The host organism uses strategies or barriers that prevent fungal diseases, such as
67 inhibiting vital fungal functions by blocking iron uptake; this is because iron is an essential
68 mineral for the proliferation of many pathogens, including *Paracoccidioides* spp. [4].

Iron is an essential component of hemoglobin (Hb), myoglobin, and several enzymes,
and it has a fundamental role in oxygen transport and electron transfer. Additionally, it acts
as a cofactor in many enzymatic processes, including DNA synthesis [5-7].

Maintaining control of iron homeostasis is essential in host-pathogen interactions because both compete for this micronutrient. During infection, some host immune mechanisms limit the availability of iron to invading microorganisms, thereby reducing their proliferation [8]. However, many microorganisms, such as *Paracoccidioides* spp., can evade the immune defense; even under limited iron conditions, they can use this mineral for growth

5

and dissemination [9]. Therefore, alterations in hematological parameters and ironmetabolism can be observed during PCM infection [10].

In the human body, iron is distributed in different interconnected forms to enable homeostasis. These forms of iron (storage iron, transport iron, and functional iron) can be evaluated separately using laboratory tests, many of which are available and accessible during routine laboratory testing. These tests can assess any disturbances in iron metabolism and the affected iron form [11]. Generally, when there is an iron deficit, these forms are sequentially affected. First, there is a decrease in the storage iron levels, followed by a deficiency in the transport iron level and a reduction in the functional iron level [12,13].

The host-parasite interaction and consequent inflammatory response lead to changes in iron metabolism dynamics. These changes can be observed in some patients with PCM [14], which is a chronic systemic inflammatory disease requiring long-term treatment. Understanding the frequency and intensity of iron metabolism disturbances in patients with chronic PCM will help improve therapeutic management. Therefore, we analyzed the iron metabolism and different iron forms of patients with chronic PCM before treatment and at the time of clinical cure.

93

# 94 Materials and Methods

## 95 **Ethical aspects**

96 This study was approved by the Human Research Ethics Committee of the Federal
97 University of Mato Grosso do Sul (CAAE number 62726016.2.0000.0021). All participants
98 provided written informed consent.

6

# 100 Location, period, and design of the study

101 This study was performed between 2013 and 2021 at the outpatient clinic for systemic 102 mycoses of the Infectious and Parasitic Diseases Unit of the University Hospital Maria 103 Aparecida Pedrossian at the Federal University of Mato Grosso do Sul, which is a reference 104 center for infectious diseases, in Campo Grande, Mato Grosso do Sul, Brazil. This analytical 105 study involving prospective data evaluated iron metabolism parameters of patients with 106 chronic PCM before treatment and at the time of clinical cure.

107

# 108 **Patients**

#### 109 Inclusion and exclusion criteria

Male and female individuals who were diagnosed with chronic PCM between September 2013 and February 2021 were included. Patients with chronic PCM who died and/or did not undergo laboratory tests at admission, such as serum iron and blood count (hemogram [HMG] test) tests, were excluded, as were patients diagnosed with human immunodeficiency virus, tuberculosis, and/or neoplasia.

#### 115 **Case definition**

116 Confirmed cases of PCM were those presenting with suggestive clinical 117 manifestations, typical yeast forms of *Paracoccidioides* spp. visualized by mycological, 118 culture, or direct histopathological tests, and/or serum-specific antibodies detected using the 119 double agar gel immunodiffusion test.

120

# 121 Demographic and clinical variables

7

Demographic, clinical, and laboratory data were retrieved from a prospective database. They comprised complete routine medical data obtained at the time of diagnosis and during follow-up of the disease. Demographic data, such as sex, age, occupational history, smoking, and clinical disease severity, were collected before treatment.

126 Chronic PCM was subdivided into mild, moderate, and severe cases. Mild cases 127 included body mass index (BMI) reduction <5% of the usual BMI and the involvement of 128 one or a few organs without functional changes. Severe cases comprised three or more of the 129 following criteria: BMI reduction  $\geq 10\%$  of the usual BMI; severe pulmonary impairment; 130 involvement of other organs, such as the adrenal glands, central nervous system, and bones: 131 enlargement of multiple lymph node chains (superficial or deep chains with pseudotumors 132 [>2.0 cm in diameter] with or without suppuration); and high-titer antibodies. Moderate cases 133 were defined as intermediate cases that were worse than mild cases but not as serious as 134 severe cases [2].

135

## 136 Laboratory analysis

Blood samples were obtained during the routine medical examination at the time of diagnosis and during follow-up. Laboratory data and complementary laboratory test data were obtained at two stages of routine outpatient follow-up: before treatment and at the time of clinical cure (disappearance of signs and symptoms) [2]. To investigate the iron metabolism of patients with chronic PCM, different forms of iron were evaluated.

142 <u>Storage iron</u>: Storage iron is iron stored in the body. Serum ferritin levels were analyzed

143 using an electrochemiluminescence immunoassay (Roche).

8

144**Transport iron**: Transport iron is iron that circulates in the body. The total iron-binding145capacity (TIBC) was measured using a colorimetric assay (Roche) and the transferrin146saturation (TSAT) level, which was calculated as [TSAT = serum iron/TIBC  $\times$  (100)]; the147result was expressed as a percentage (%).

148 **Functional iron:** Functional iron is related to erythrocyte synthesis and erythropoiesis.

149 Therefore, to evaluate functional iron, the blood count (HMG test) was evaluated to measure

150 the Hb level, red blood cell (RBC), level mean corpuscular volume, and mean Hb

151 concentration (MHC) (XN 3000 series hematology equipment; Sysmex Corporation, Kobe,

152 Japan). Serum iron was determined using a colorimetric assay (Roche). The soluble

153 transferrin receptor (sTfR) level was determined using an enzyme-linked immunosorbent

154 assay (human sTfR ELISA Kit; Elabscience). This test is not routinely performed; therefore,

serum stored in the PCM biobank was used.

156 The inflammatory process was assessed according to the high-sensitivity serum C-

157 reactive protein (CRP) level measured using immunoturbidimetry. All analyzed parameters

and values considered normal by the manufacturer are listed in **Table 1**.

9

### 160 Table 1. Iron parameters and reference values provided by the manufacturer.

Parameters	Reference values
Storage iron	
Serum ferritin	Males: 30-400 ng/mL
	Females: 13-150 ng/mL
Transport iron	
Transferrin saturation	30%-50%
Total iron-binding capacity	250-410 μg/dL
Functional iron	
Total erythrocyte count (red blood cells)	4.5-5.9 million/mm <sup>3</sup>
Hemoglobin	13.5-17 g/dL
Hematocrit	41%-53%
Mean corpuscular volume	82 fL
Mean hemoglobin concentration	25-34 pg
Serum iron	61-157 μg/dL
Soluble transferrin receptor	16.79-172.63 ng/mL
Inflammatory process	
C-reactive protein	0-5.0 mg/L

# 162 Statistical analysis

163	The statistical data analysis was performed using Jamovi software (version 1.6) for
164	Windows [15]. Data are presented as the mean $\pm$ standard deviation (SD) or median with the
165	first quartile (Q1) and third quartile (Q3). Comparisons between values before treatment and
166	at the time of clinical cure were performed using Student's t test or the Wilcoxon signed rank
167	test. The Pearson correlation coefficient I was used to determine the relationship between
168	variables; values $\leq 0.29$ , between 0.30 and 0.49, and between 0.50 and 1.0 were considered
169	weak, moderate, and strong correlations, respectively.
170	McNemar's test was performed to assess the associations between qualitative
171	variables. The Shapiro-Wilk test was performed to determine whether the variables were
172	normally distributed.
173	A proportion test and one-sample test were performed to analyze the categorical and
174	numerical variables, respectively. For all tests, $p \le 0.05$ was considered significant.
175	
176	Results
177	A total of 88 patients were diagnosed with chronic PCM during the study period. Of
178	these, 35 patients were excluded according to the criteria and 39 patients participated in the
179	study (Fig 1). The mean age of these patients was 54.5 years (SD, 6.70 years); 38 (97.4%)
180	were men and 35 (92.1%) were rural workers. Thirty-three (84.6%) individuals were smokers
181	at the time of diagnosis. Regarding disease severity, 66.7% of the patients had moderate

182 disease, 20.5% had severe disease, and 12.8% had mild disease (Table 2).

11

#### 184 Fig 1. Flowchart of the selection of participants with chronic paracoccidioidomycosis

- 185 (PCM) from 2013 to 2021.
- 186 HIV, human immunodeficiency virus.
- 187

12

#### 188 Table 2. Baseline demographic, clinical, and lifestyle data of 39 patients with chronic

#### 189 paracoccidioidomycosis.

Variables	n (%) or mean		95% CI	р
	(SD)			
Sex				< 0.001
Male	38 (97.4)	86.5	99.9	
Female	1 (2.6)	0.06	13.5	
Age (in years)*	54.5 (6.70)	52.3	56.6	<0.001†
Rural workers (n = 38)				< 0.001
Previous/current	35 (92.1)	78.6	98.3	
Never	3 (7.9)	1.6	21.4	
Cigarette smoking				< 0.001
Current	33 (84.6)	69.5	94.1	
Previous	4 (10.3)	2.9	24.2	
Never	2 (5.1)	0.6	17.3	
Severity				< 0.001
Moderate	26 (66.7)	49.8	80.9	
Severe	8 (20.5)	9.3	36.5	

13

Mild	5 (12.8)	4.3	27.4	
Initial treatment				0.002
Itraconazole	29 (74.4)	57.9	87.0	
СМХ	10 (25.6)	13.0	42.1	
*Mean. CI, confidence interval; CMX, cotr	imoxazole or	trimethop	rim/sulfame	thoxazole;

191 SD, standard deviation. Proportion test:  $\chi^2$  goodness of fit. †One-sample t test.

192

190

## 193 Storage iron

Nine (26.5%) patients had increased ferritin levels and two (5.8%) patients had lower than normal ferritin levels before treatment (evaluated before treatment: n = 34 patients). An analysis of patients who were evaluated at both time points (before treatment and at the time of clinical cure: n = 28 patients) showed that the number of individuals with high ferritin levels decreased (21.4% before treatment vs. 17.9% at the time of clinical cure; p = 0.008). An analysis of the median values showed that those at the time of clinical cure were reduced compared to those before treatment (p = 0.017) (**Fig 2**).

201

202



204 time of clinical cure (CC) of patients with chronic paracoccidioidomycosis.

205 Q1, first quartile; Q3, third quartile. Wilcoxon signed rank test.

206

# 207 **Transport iron**

208	Transport iron was evaluated according to the TSAT level and TIBC. Of the 39
209	patients evaluated before treatment, 27 (69.2%) had TSAT levels <30% and 8 (20.5%) had
210	TSAT levels <16%. At the time of clinical cure, the number of patients with TSAT levels
211	<30% (n = 12; 42.9%) did not decrease (before treatment vs. clinical cure: n = 28; p = 0.071).
212	Similarly, an analysis of the median TSAT values showed no statistical differences between
213	those before treatment and those at the time of clinical cure (Table 3).
214	The TIBC analysis showed that 22 (56.4%) individuals had lower than normal values
215	before treatment ( $n = 39$ ). At the time of clinical cure, the number of individuals with TIBC
215 216	before treatment (n = 39). At the time of clinical cure, the number of individuals with TIBC lower than the reference value had not decreased (n = 10; 35.7%; $p = 0.439$ ). An analysis of
215 216 217	before treatment (n = 39). At the time of clinical cure, the number of individuals with TIBC lower than the reference value had not decreased (n = 10; 35.7%; p = 0.439). An analysis of the mean values before treatment showed that the TIBC was slightly lower than normal, and
215 216 217 218	before treatment (n = 39). At the time of clinical cure, the number of individuals with TIBC lower than the reference value had not decreased (n = 10; 35.7%; p = 0.439). An analysis of the mean values before treatment showed that the TIBC was slightly lower than normal, and that it had not increased at the time of clinical cure ( <b>Table 3</b> ).

15

#### 220 Table 3. Comparison of mean or median values of the transport iron parameters before

221 treatment and at the time of clinical cure of 30 patients with chronic

222 paracoccidioidomycosis.

Variables	Before Tr	Before Treatment		Clinical Cure		
	Mean or	SD or	Mean or	SD or		
	Median	Q1-Q3	Median	Q1-Q3		
TSAT (%)	26	18.0 - 36.8	32.5	24.3-40.0	0.076	
TIBC (µg/dL)	245	100.9	265	85.7	0.398	

Q1, first quartile; Q3, third quartile; SD, standard deviation; TIBC, total iron-binding
capacity; TSAT, transferrin saturation. The Wilcoxon signed rank test and paired Student's t
test were performed.

226

## 227 Functional iron

The HMG test was performed to evaluate the Hb, RBC, and HCT levels, mean corpuscular volume, and mean corpuscular Hb level to assess functional iron. Additionally, to complement this evaluation, the serum iron and sTfR values and sTfR/log ferritin ratio were calculated.

The HMG test results before treatment (n = 39) showed that 36% (n = 14) of individuals had reduced Hb, RBC, and HCT levels. Anemia was considered when the Hb level was <13.5 g/dL. It was noted that 46.1% (n = 18) of patients had anemia; among these patients, 72% (n = 13) had normocytic and normochromic anemia. The mean Hb level among the 18 patients with anemia was 11.2 g/dL (SD, 1.21 g/dL).

237	During the healing process of these patients, the anemia frequency and HCT levels
238	were significantly reduced (Table 4). These improvements with treatment were also
239	observed when evaluating the mean values, which were significantly increased at the time of
240	clinical cure compared to those before treatment (Table 5).
241	Before treatment, more than half of the patients ( $n = 22$ ; 56.4%) had lower than normal
242	serum iron levels; however, at the time of clinical cure, the percentage of patients with lower
243	than normal serum iron levels was significantly reduced (Table 4). It was also noted that the
244	mean values of these patients increased significantly with the use of antifungal treatment
245	(Table 5). The sTfR levels and sTfR/log ferritin ratios before treatment and at the time of
246	clinical cure were not significantly different (Table 5).

17

### 248 Table 4. Changes in functional iron parameters at the time of clinical cure compared to

Variables	<b>Before Treatment</b>	<b>Clinical Cure</b>	р
	n (%)	n (%)	
Anemia	14 (40.0)	6 (17.1)	0.011
Reduced RBCs	16 (45.7)	11 (31.4)	0.132
Reduced HCT	18 (51.4)	11 (31.4)	0.035
Reduced iron*	15 (51.7)	4 (12.5)	< 0.001

#### 249 those before treatment of 35 patients with chronic paracoccidioidomycosis.

\*Iron evaluation of 32 patients. The McNemar test was performed. HMG: hemogram; RBCs, red blood cells (total erythrocyte count); HCT, hematocrit.

250

18

#### 252 Table 5. Comparison of functional iron parameter values before treatment and at the

Variables		Before	Treatment		(	Clinical Cure	р
	n	Mean or	SD or	n	Mean or	SD or	
		Median	Q1-Q3		Median	Q1-Q3	
Hb	35	13.1	2.2	35	14.5	1.8	< 0.001
RBCs	35	4.5	0.6	35	4.8	0.6	0.002
НСТ	35	39.9	6.1	35	43.6	5.2	< 0.001
MCV	35	89.0	5.7	35	91.0	5.3	0.093
МСН	35	29.3	2.3	35	30.4	2.2	0.008
Iron	32	64.0	37.0-88.5	32	85.5	69.0-109.0	0.004
sTfR	18	21.5	17.4-7.6	18	16.2	6.3-20.2	0.099
sTfR/logFerr	11	8.1	2.8	11	7.6	3.9	0.660

#### 253 time of clinical cure of patients with chronic paracoccidioidomycosis.

SD, standard deviation; Q1, first interquartile; Q3, third interquartile; Hb, hemoglobin;
RBCs, red blood cells (total erythrocyte count); HCT, hematocrit; MCV, mean corpuscular
volume; MCH, mean hemoglobin concentration; sTfR, soluble transferrin receptor; sTfR/log
Ferr index, soluble transferrin receptor index/ferritin logarithm. The Wilcoxon signed rank
test and paired Student's t test were performed.

19

# 259 Inflammatory process

280	treatment (n = 36 patients).
279	evaluate the iron forms of patients with chronic paracoccidioidomycosis before
278	Fig 4. Pearson's correlations of C-reactive protein (CRP) with variables used to
277	
276	observed between the CRP levels and these variables.
275	0.491; $p = 0.002$ ) were observed (Fig 4). At the time of clinical cure, no correlations were
274	RBC level (r = -0.461; p = 0.005), HCT level (r = -0.514; p = 0.001), and iron level (r = -
273	(before treatment) and the TIBC (r = -0.405; p = 0.014), Hb level (r = -0.500; p = 0.002),
272	Weak to moderate indirect correlations between CRP levels during active disease
271	
270	rank test.
269	Q1, first quartile; Q3, third quartile; BT, before treatment; CC, clinical cure. Wilcoxon signed
268	stages of PCM.
267	Fig 3. Boxplot of the inflammatory process evaluation involving CRP during different
266	
265	3).
264	reduction in the values at the time of clinical cure compared to those before treatment (Fig
263	However, an analysis of the median values of each disease stage showed a significant
262	values outside the normal range had not decreased significantly ( $n = 7$ ; 21.9%; $p = 0.225$ ).
261	range before treatment ( $n = 32$ ). At the time of clinical cure, the percentage of patients with
260	More than half of the patients ( $n = 20$ ; 62.5%) had values higher than the normal

20

281 (a	a) CRP with the total	iron-binding capa	city (TIBC).	(b) CRP with	hemoglobin	(Hb). (	(c) CRP
--------	-----------------------	-------------------	--------------	--------------	------------	---------	---------

- with red blood cells (RBCs; total erythrocyte count). (d) CRP with hematocrit (HCT).
- 283 An analysis of the stored iron and functional iron parameters before treatment showed
- a significant difference between values associated with severe and mild/moderate disease
- cases as well as CRP levels (**Table 6**).

21

#### 287 Table 6. Analysis of iron parameters and CRP levels according to disease severity of

Variables	Severe (n = 08)	Mild or Moderate (n = 31)	р
	Mean (SD) or	Mean (SD) or	
	Median [Q1-Q3]	Median [Q1-Q3]	
Storage iron			
Ferritin	448 [308-514]	199 [90.4-290]	0.007
Transport iron			
TSAT	18 [14.3-22.8]	27 [18-38.2]	0.051
TIBC	215 [191-245]	241 [201-310]	0.258
Functional iron			
RBCs	4.05 (0.81)	4.60 (0.57)	0.031
Hb	11.8 (3.1)	13.5 (1.8)	0.050
НСТ	35.8 (8.8)	41.0 (4.8)	0.029
Iron	40.4 (14.5)	68.1 (35.5)	0.039
CRP	51.7 [40.8-71.4]	7.06 [2.90-20.1]	< 0.001

#### 288 patients with chronic paracoccidioidomycosis before treatment.

Q1, first quartile; Q3, third quartile; TSAT, transferrin saturation; TIBC, total iron-binding
capacity; RBC, red blood cells (total erythrocyte count); Hb, hemoglobin; HCT, hematocrit;
CRP, C-reactive protein. The Mann-Whitney U test and independent Student's t test were
performed.

293

294

# 295 **Discussion**

The acquisition of iron by microorganisms is an important virulence mechanism [16],and it has been reported with *Paracoccidioides* spp. [9, 17]. Additionally, human organisms

22

298 actively control intracellular and systemic iron levels in a way that can contain infection 299 and/or microbial persistence. Therefore, this study compared iron metabolism parameters 300 before treatment and at the time of clinical cure, analyzed them based on PCM severity, and 301 correlated them with the intensity of the inflammatory process in patients with chronic PCM. 302 The demographic and clinical characteristics of the patients corresponded to those 303 reported by other case series studies of chronic PCM that involved mostly male patients who 304 were older than age 40 years, smokers, rural workers, and had moderate PCM [18-22]. 305 Therefore, this sample is representative of the population of PCM patients and allows the 306 generalization of our results.

307 The storage iron evaluated during this study had higher median serum ferritin levels 308 before treatment, but they were within the normal range. Although ferritin exists in large 309 amounts in the liver and spleen, only a small amount is detected in the circulation. However, 310 serum quantification is a common and non-invasive method that provides an accurate 311 measurement of storage iron [23]. However, the increase in serum ferritin may be related not 312 only to increased storage iron but also to inflammatory activity. Because serum ferritin is an 313 acute-phase protein in inflammatory and infectious processes and in cancer, the production 314 of apoferritin is increased because of the stimulation of interleukins (ILs) such as IL-1 and 315 IL-6 [24]. Increases in these ILs have been observed in patients with PCM [25].

During this study, serum ferritin levels were increased in some patients; however, the median values were within the normal range before treatment. At the time of clinical cure, these median values were significantly decreased, suggesting the interference of PCM with this parameter. Additionally, severe cases were associated with higher ferritin levels, probably because of the production of IL-6 caused by fungal infection. A previous study by our group reported similar results [14].

23

322 To assess the transport iron, we evaluated the TIBC, TSAT level, and serum 323 iron/TIBC ratio. Before treatment, the patients in this study had median values that were 324 slightly lower than normal, indicating a non-significant transport iron deficit. Additionally, 325 antifungal therapy did not affect these parameters. A weak negative correlation was observed 326 between the TIBC and CRP level, but no correlation was observed between the TSAT and 327 CRP levels. The TIBC is an indirect measure of circulating transferrin, which can be reduced 328 during inflammatory processes [11]. Therefore, with chronic PCM, the transport iron 329 parameters are less affected than the storage iron and functional iron parameters.

330 A TSAT level <16% is considered indicative of iron deficiency with erythropoiesis: 331 however, the use of this value for this parameter has limitations because both iron levels and 332 the TIBC are lower with inflammatory processes [12, 23]. During our study, TSAT values 333 <16% were found in 8 (20.5%) patients before treatment. However, only one of them had 334 confirmed iron deficiency anemia, which is characterized by low Hb, ferritin, and TSAT 335 levels [26]. A study of the effect of PCM treatment on iron metabolism showed that specific 336 treatment quickly leads to a return to normal values or improvement in iron metabolism, as 337 described with the TIBC, which was lower and normalized soon before antifungal treatment 338 [27].

In clinical practice, the HMG test results and serum iron level are the first indicators of a change in the iron status. Although our study showed that the parameter values were slightly or not altered before treatment, it was possible to infer that PCM interferes with functional iron because these values improved after treatment and were associated with PCM severity. Additionally, a moderate correlation was observed between Hb, RBC, HCT, iron, and CRP levels. Furthermore, similar to our results, tuberculosis patients with active disease had lower mean values of these variables [28].

24

Approximately 65% of the total body iron in circulation in humans is linked to Hb 347 [7], and reduced Hb with chronic infectious diseases is attributable to the limitation of 348 erythropoiesis caused by regulators such as IL-1 and tumor necrosis factor- $\alpha$  [29]. Hb is a 349 source of iron for *Paracoccidioides* spp., which removes iron by hemolytic activity and 350 internalizes protoporphyrin rings through receptor-mediated pathways [30]. Other fungi are 351 also capable of removing iron from Hb, such as *Candida albicans*, through a similar 352 mechanism [31].

353 During infection, competition between the pathogen and host for iron uptake involves 354 strategic mechanisms. Therefore, in response to infection, human organisms activate the 355 immune system, thus inducing changes in circulating iron and leading to iron storage in 356 macrophages and decreased absorption of iron from the diet by enterocytes [32]. 357 Furthermore, several inflammatory cytokines are released by immune system cells, and they 358 contribute to alterations in iron metabolism [33]. Despite the host-generated deprivation of 359 iron, all fungi, including *Paracoccidioides* spp., have specific mechanisms for iron uptake 360 through the production of molecules with high affinity for iron, siderophores, iron uptake 361 pathways through reductive iron assimilation, or even Hb receptors [9, 34, 35]. Therefore, an 362 inflammatory response associated with infection alters the availability of circulating iron, 363 thus increasing its intracellular storage and leading to hypoferremia and iron-restricted 364 erythropoiesis, as observed during our study, because these changes can contribute to anemia 365 of inflammation [36].

The sTfR level is a good indicator of the iron status in the absence of systemic influences; therefore, we analyzed sTfR levels before treatment and at the time of clinical cure. Our results showed that the median values before treatment were normal and did not decrease after treatment, suggesting that the body iron is normal; however, it is distributed

370 from functional iron to storage iron. A high sTfR level can indicate iron deficiency [37, 38]. 371 During the storage iron reduction phase, the sTfR level does not change. However, when 372 there is a decrease in functional iron, the synthesis of the transferrin receptor is stimulated; 373 consequently, the sTfR level increases. This parameter is mainly recommended for 374 differentiating iron deficiency anemia from inflammation anemia/chronic disease anemia 375 because the value is increased with iron deficiency anemia but normal with inflammation 376 anemia [39-41]. Studies of pulmonary tuberculosis patients suggested that high sTfR levels 377 in patients with anemia indicate probable iron deficiency and recommended that the sTfR 378 concentration of patients with anemia and an infectious/inflammatory process should be 379 examined [28].

Another good indicator of iron deficiency with differential anemia is the sTfR/log ferritin ratio [42]. During our study, the sTfR/log ferritin ratio as well as sTfR level were normal before treatment and did not significantly change after treatment, reinforcing the belief that anemia with chronic PCM is inflammation anemia.

This study presents some limitations. The number of patients is apparently low. However, our Service receives about 15 new cases every year and most of the patients do not undergo the follow-up after clinical improvement, becoming difficult the pairing of some variables – before treatment and after clinical cure.

In conclusion, PCM interferes with iron metabolism by shifting functional iron to storage iron, as revealed by anemia and low iron levels, with normal TSAT and sTfR levels, normal TIBC, and normal sTfR/log ferritin ratio. Normal or slightly increased ferritin levels, which are characteristic of inflammatory anemia, were observed. However, it should be noted that a few patients had iron deficiency anemia. Therefore, a careful investigation of the iron parameters is important to the clinical management of PCM.

26

#### 394

# 395 **References**

- 396 1. Coutinho ZF, Silva D da, Lazéra M, Petri V, Oliveira RM de, Sabroza PC, et al.
- 397 [Paracoccidioidomycosis mortality in Brazil (1980-1995)]. Cad Saúde Pública.
- **398** 2002;18(5):1441–54.
- 2. Mendes RP, Cavalcante R de S, Marques SA, Marques MEA, Venturini J, Sylvestre TF,
- 400 et al. Paracoccidioidomycosis: Current Perspectives from Brazil. TOMicroJ.
- **401** 2017;11(1):224–82.
- 402 3. Benard G. Pathogenesis and Classification of Paracocidioidomycosis: New Insights From
- 403 Old Good Stuff. Open Forum Infect Dis. 2021;8(3):624.
- 404 4. Bailão EFLC, Lima P de S, Silva-Bailão MG, Bailão AM, Fernandes G da R, Kosman
- 405 DJ, et al. Paracoccidioides spp. ferrous and ferric iron assimilation pathways. Front
- 406 Microbiol. 2015;6. doi: 10.3389/fmicb.2015.00821.
- 407 5. DuBois S, Kearney DJ. Iron-Deficiency Anemia and Helicobacter pylori Infection: A
- 408 Review of the Evidence. Am J Gastroenterology. 2005;100(2):453–9.
- 409 6. Zhang C. Essential functions of iron-requiring proteins in DNA replication, repair and cell
- 410 cycle control. Protein Cell. 2014;5:750–760. doi:10.1007/s13238-014-0083-7.
- 411 7. Gupta C P. Role of iron (Fe) in body. IOSR Journal of Applied Chemistry. 2014;7(11):
- **412** 38-46.
- 413 8. Appelberg R. Macrophage nutriprive antimicrobial mechanisms. J Leukoc Biol.
  414 2006;79(6):1117–28.
- 415 9. Silva-Bailão MG, Bailão EFLC, Lechner BE, Gauthier GM, Lindner H, Bailão AM, et al.
- 416 Hydroxamate Production as a High Affinity Iron Acquisition Mechanism in

- 417 *Paracoccidioides* spp. Roop RM, organizador. PLoS ONE. 2014;9(8):e105805.
- 418 10. Ozaki KS, Munhoz Júnior S, Pinheiro EK, Tadano T, Fontes CJF. [The diagnosis of
- 419 severe disseminated paracoccidioidomycosis in a bone marrow aspirate: a case report]. Rev
- 420 Soc Bras Med Trop. 1996;29(4):363–6.
- 421 11. Wians FH, Urban JE, Keffer JH, Kroft SH. Discriminating Between Iron Deficiency
- 422 Anemia and Anemia of Chronic Disease Using Traditional Indices of Iron Status vs
- 423 Transferrin Receptor Concentration. Am J Clin Pathol. 2001;115(1):112–8.
- 424 12. Cook JD. Clinical evaluation of iron deficiency. Semin Hematol. 1982;19(1):6–18.
- 425 13. Cook J. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin
- 426 Haematol. 2005;18(2):319–32.
- 427 14. de Oliveira Custódio JM, Enokida IM, Gonçalves DA, Leone de Oliveira SM do V,
- 428 Venturini J, Carvalho LR, et al. Dynamics of plasma micronutrient concentrations and their
- 429 correlation with serum proteins and thyroid hormones in patients with430 paracoccidioidomycosis. Vicente CR, organizador. PLoS ONE. 2019;14(12):e0226609.
- 431 15. The jamovi project. Jamovi. 2021. Available in: https://www.jamovi.org.
- 432 16. Nevitt T. War-Fe-re: iron at the core of fungal virulence and host immunity. Biometals.
  433 2011;24(3):547–58.
- 434 17. Parente AFA, Bailão AM, Borges CL, Parente JA, Magalhães AD, Ricart CAO, et al.
- 435 Proteomic analysis reveals that iron availability alters the metabolic status of the pathogenic
- 436 fungus *Paracoccidioides brasiliensis*. PLoS One. 2011;6(7):e22810.
- 437 18. Fabris LR, Andrade ÚV, Santos AFD, Marques AP da C, Oliveira SM do VL de, Mendes
- 438 RP, et al. Decreasing prevalence of the acute/subacute clinical form of
- 439 paracoccidioidomycosis in Mato Grosso do Sul State, Brazil. Rev Inst Med trop S Paulo.

**440** 2014;56(2):121–5.

- 441 19. Queiroz-Telles F, Escuissato DL. Pulmonary paracoccidioidomycosis. Semin Respir Crit
  442 Care Med. 2011;32(6):764–74.
- 443 20. Matos WB de, Santos GMC dos, Silva VEB da, Gonçalves E da G do R, Silva AR da.
- 444 Paracoccidioidomycosis in the state of Maranhão, Brazil: geographical and clinical aspects.
- 445 Rev Soc Bras Med Trop. 2012;45(3):385–9.
- 446 21. Peçanha PM, Batista Ferreira ME, Massaroni Peçanha MA, Schmidt EB, Lamas de
- 447 Araújo M, Zanotti RL, et al. Paracoccidioidomycosis: Epidemiological and Clinical Aspects
- 448 in 546 Cases Studied in the State of Espírito Santo, Brazil. Am J Trop Med Hyg.
- **449** 2017;97(3):836–44.
- 450 22. dos Santos WA, da Silva BM, Passos ED, Zandonade E, Falqueto A. [Association
- 451 between smoking and paracoccidioidomycosis: a case-control study in the State of Espírito
- 452 Santo, Brazil]. Cad Saude Publica. 2003;19(1):245–53.
- 453 23. Cook JD, Baynes RD, Skikne BS. Iron deficiency and the measurement of iron status.
- 454 Nutr Res Rev. 1992;5(1):198–202.
- 455 24. Baynes RD. Assessment of iron status. Clinical Biochemistry. 1996; 29 (3): 209–15.
- 456 25. Leal AMO, Magalhães PKR, Martinez R, Moreira AC. Adrenocortical hormones and
- 457 interleukin patterns in paracoccidioidomycosis. J Infect Dis. 2003;187(1):124–7.
- 458 26. Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the
- 459 hepcidin era. Haematologica. 2020;105(2):260–72.
- 460 27. Martinez R, Fiorillo AM. [Effect of treatment of South American blastomycosis
- 461 (paracoccidioidomycosis) on parameters of iron metabolism]. Rev Inst Med Trop Sao Paulo.
- 462 1978;20(4):190–4.
- 463 28. Ratnaningsih T, Sukirto NW, Wahyuningsih AT. Soluble Transferrin Receptor (sTfR)
- 464 Identifies Iron Deficiency Anemia (IDA) in Pulmonary Tuberculosis Patients. Acta Med

- 465 Indones. 2020;52(4):334–43.
- 466 29. Means RT. Advances in the anemia of chronic disease. Int J Hematol. 1999;70(1):7–12.
- 467 30. Bailão EFLC, Parente JA, Pigosso LL, Castro KP de, Fonseca FL, Silva-Bailão MG, et
- 468 al. Hemoglobin Uptake by Paracoccidioides spp. Is Receptor-Mediated. Vinetz JM,
- 469 organizador. PLoS Negl Trop Dis. 2014;8(5):e2856.
- 470 31. Kuznets G, Vigonsky E, Weissman Z, Lalli D, Gildor T, Kauffman SJ, et al. A relay
- 471 network of extracellular heme-binding proteins drives C. albicans iron acquisition from
- 472 hemoglobin. PLoS Pathog. 2014;10(10):e1004407.
- 473 32. Muckenthaler MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism.
- 474 Cell. 2017;168(3):344–61.
- 475 33. Symeonidis AS. The role of iron and iron chelators in zygomycosis. Clin Microbiol
- 476 Infect. 2009;15 Suppl 5:26–32.
- 477 34. Stanford FA, Voigt K. Iron Assimilation during Emerging Infections Caused by
- 478 Opportunistic Fungi with emphasis on Mucorales and the Development of Antifungal479 Resistance. Genes (Basel). 2020;11(11):e1296.
- 480 35. Misslinger M, Hortschansky P, Brakhage AA, Haas H. Fungal iron homeostasis with a
- 481 focus on Aspergillus fumigatus. Biochim Biophys Acta Mol Cell Res. 2021;1868(1):118885.
- 482 36. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40–50.
- 483 37. Baillie FJ, Morrison AE, Fergus I. Soluble transferrin receptor: a discriminating assay for
- 484 iron deficiency. Clin Lab Haematol. 2003;25(6):353–7.
- 485 38. Punnonen K, Irjala K, Rajamäki A. Iron-deficiency anemia is associated with high
- 486 concentrations of transferrin receptor in serum. Clin Chem. 1994;40(5):774–6.
- 487 39. Worwood M. Serum transferrin receptor assays and their application. Ann Clin Biochem.
- **488** 2002;39(3):221–30.

30

- 489 40. Peng YY, Uprichard J. Ferritin and iron studies in anaemia and chronic disease. Ann Clin
  490 Biochem. 2017;54(1):43–8.
- 491 41. Infusino I, Braga F, Dolci A, Panteghini M. Soluble transferrin receptor (sTfR) and
- 492 sTfR/log ferritin index for the diagnosis of iron-deficiency anemia. A meta-analysis. Am J
- **493** Clin Pathol. 2012;138(5):642–9.
- 494 42. Skikne BS, Punnonen K, Caldron PH, Bennett MT, Rehu M, Gasior GH, et al. Improved
- 495 differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective
- 496 multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J
- **497** Hematol. 2011;86(11):923–7.
- 498

# 499 Supporting information

- 500 S1 Dataset. Dataset containing variables of the study.
- 501

which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

# Chronic PCM patients, n = 88



Enrolled PCM patients, n = 39

# Figure



Figure



# Figure

# a) TIBC



150

150

d) HCT

Iron e) Pearson's r = -0.491 p = 0.002 Pearson's r = -0.514 p = 0.001 60-150-50-Iron (ug/dL) 100-+\$ 50-30-٠ ٠ 0 150 100 100 50 0 50 0 CRP (mg/L) CRP (mg/L)

Figure

20

Hematocrit (%)